TY - JOUR
T1 - Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma
AU - Calzada, Oscar
AU - Switchenko, Jeffrey M.
AU - Maly, Joseph J.
AU - Blum, Kristie A.
AU - Grover, Natalie
AU - Mathews, Stephanie
AU - Park, Steven I.
AU - Gordon, Max
AU - Danilov, Alexey
AU - Epperla, Narendranath
AU - Fenske, Timothy S.
AU - Hamadani, Mehdi
AU - Flowers, Christopher R.
AU - Cohen, Jonathon B.
N1 - Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/12/2
Y1 - 2018/12/2
N2 - Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p =.001), have no B symptoms (83 versus 65% p =.003) and have normal LDH levels at diagnosis (87 versus 55% p <.001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22–1.84, p =.407).
AB - Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p =.001), have no B symptoms (83 versus 65% p =.003) and have normal LDH levels at diagnosis (87 versus 55% p <.001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22–1.84, p =.407).
KW - Mantle cell lymphoma
KW - deferred therapy
KW - non-Hodgkin’s lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85048791473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048791473&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1455973
DO - 10.1080/10428194.2018.1455973
M3 - Article
C2 - 29912594
AN - SCOPUS:85048791473
SN - 1042-8194
VL - 59
SP - 2862
EP - 2870
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -